Syros Pharmaceuticals, Inc. stock is up 46.43% since 30 days ago. The next earnings date is Feb 29, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 37.5% of the previous 7 December’s closed higher than November.
Syros Pharmaceuticals, Inc. focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome.